Volume 12, Issue 6, Pages 644-647 (June 2013) Cell Therapy Companies Make Strong Progress from October 2012 to March 2013 Amid Mixed Stock Market Sentiment Chris Mason, Julian Mason, Emily J. Culme-Seymour, Gregory A. Bonfiglio, Brock C. Reeve Cell Stem Cell Volume 12, Issue 6, Pages 644-647 (June 2013) DOI: 10.1016/j.stem.2013.05.017 Copyright © 2013 Elsevier Inc. Terms and Conditions
Figure 1 Cell Therapy Index for Q4 2012 and Q1 2013 The index is composed of cell therapy companies with market capitalizations greater than $50M. It commences on October 1, 2012 with a benchmark value set at 1,000. The major established biotechnology indices (BTK and NBI) are included and demonstrate that the cell therapy industry is a unique investment class and thus distinct from biotech. See also Table S1. Cell Stem Cell 2013 12, 644-647DOI: (10.1016/j.stem.2013.05.017) Copyright © 2013 Elsevier Inc. Terms and Conditions